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ABSTRACT
Background    High-risk prostate cancer treatment 
has been controversial. Some high-risk prostate cancer 
patients fail to respond to radical prostatectomy only. 
Thus, we aimed to investigate the predictive factors for 
biochemical recurrence (BCR) and identify patients who 
could achieve sufficient therapeutic effect by radical 
prostatectomy only.
Methods    Of 264 medical records reviewed, 141 
low-intermediate-risk and 100 high-risk prostate cancer 
patients, excluding those who had received neoadjuvant 
hormone therapy, were analyzed. BCR was defined as 
the first increase in prostate-specific antigen levels (≥ 
0.2 ng/mL), with levels not decreasing to undetectable 
limits, after radical prostatectomy. Log-rank test and 
Cox proportional hazards regression analyses were per-
formed to determine the prognostic factors. We investi-
gated the perioperative predictive factors for BCR and 
BCR-free survival rates, with the number of National 
Comprehensive Cancer Network (NCCN) high-risk fac-
tors for high-risk prostate cancer patients who underwent 
robot-assisted radical prostatectomy.
Results    Multivariate analyses showed that clinical T3 
was significantly associated with BCR [hazard ratio (HR) 
= 4.052; 95% confidence interval (CI), 1.26–12.99; P = 
0.019]. Of the 100 patients, 77 had 1 high-risk factor and 
23 had ≥ 2 high-risk factors; the 1-year BCR-free surviv-
al rate of patients with 1 high-risk factor and those with 
≥ 2 high-risk factors was 94.8% and 69.6%, respectively. 
Patients with ≥ 2 high-risk factors were significantly 
associated with BCR (P = 0.002). No difference in BCR 
rate between patients with 1 high-risk factor and those 
with low- and intermediate-risk was found.
Conclusion    High-risk prostate cancer patients with 1 
NCCN high-risk factor can be considered for robot-as-
sisted radical prostatectomy treatment only.
Key words    biochemical recurrence; high-risk prostate 
cancer; robot-assisted radical prostatectomy
High-risk prostate cancer treatment has been contro-
versial. Surgical treatment results in high biochemical 
recurrence (BCR) rates; thus, some studies have report-
ed that a combination of hormone therapy and radiation 
therapy (RT; external beam radiation or brachytherapy)1 
or radical prostatectomy and adjuvant RT after preoper-
ative hormone therapy is effective in high-risk prostate 
cancer.2 The decision on whether to elect surgery as the 
local therapy should be based on the best available clin-
ical evidence in the European Association of Urology 
(EAU) guidelines.3 Although a combination of hormone 
therapy and RT is one of the recommended treatments, 
adverse events due to RT and long-term hormone thera-
py, such as radiation cystitis, rectal breeding, liver dys-
function, hot flush, and glucose intolerance, pose a prob-
lem for prostate cancer patients. Such adverse effects 
are addressed by robot-assisted radical prostatectomy 
(RARP) as the first-line therapy for prostate cancer pa-
tients.4 Although we might perform radical prostatecto-
my as local therapy for high-risk prostate cancer patients 
who caused a BCR after long-term androgen deprivation 
therapy (ADT) and/or RT, it might be associated with 
increasing high complications by the adhesion of the 
organization. On the other hand, it is easier to add hor-
mone therapy and RT for patients who underwent rad-
ical prostatectomy.5 Thus, identifying the patients who 
could achieve the sufficient therapeutic effect by radical 
prostatectomy only is essential. 
 We hypothesized that high-risk prostate cancer pa-
tients with only 1 National Comprehensive Cancer Net-
work (NCCN) high-risk factor can benefit from surgical 
treatment only.6 We investigated the predictive factors 
for BCR and BCR-free survival rates with the number 
of NCCN high-risk factors for high-risk prostate cancer 
patients who underwent RARP.
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MATERIALS AND METHODS
Patients and data collection
We reviewed the medical records of 264 patients who 
underwent RARP between October 2010 and September 
2015. The study protocol was approved by the Institu-
tional Review Board of the Tottori University Faculty of 
Medicine (Approval No. 2008). We excluded 23 patients 
who had undergone neoadjuvant hormone therapy and, 
consequently, analyzed 141 low-intermediate-risk and 
100 high-risk prostate cancer patients. The NCCN risk 
classification of the 241 patients was as follows: low risk, 
32 (13.3%); intermediate risk, 109 (45.2%); and high risk, 
100 (41.5%). Patients in the high-risk prostate cancer 
group had at least one of the following high-risk factors: 
prostate-specific antigen (PSA) ≥ 20 ng/mL, clinical T3 
(cT3), and Gleason score (GS) ≥ 8 and were subsequent-
ly divided into two groups, according to the number of 
NCCN high-risk factors, i.e., 1 high-risk factor and ≥ 2 
high-risk factor groups.
Surgical technique
The operation was performed using a standard 6-port, 
trans-peritoneal technique, employing the da Vinci S 
and da Vinci Si surgical robotic system (Intuitive Sur-
gery, Sunnyvale, CA). Of the 100 high-risk prostate 
cancer patients, 66 (66.0%) patients underwent extend-
ed lymph node dissection, which includes the external 
iliac, obturator, and internal iliac lymph nodes, and 34 
(34.0%) patients underwent limited node dissection, i.e., 
including the obturator lymph nodes only. Although 
extended lymph node dissection for high-risk prostate 
cancer patients has been recommended in the EAU 
guidelines,3 limited node dissection was performed in 
the 34 patients because of initial RARP case and patient 
complications. Of the 141 low-intermediate-risk prostate 
cancer patients, 101 (71.6%) patients underwent limited 
node dissection; the rest have not undergone lymph node 
dissection.
 In this study, the nerve preservation group composed 
of both the unilateral and bilateral nerve preservation. 
The clinical stage of the 241 patients was evaluated us-
ing computed tomography, magnetic resonance imaging, 
and bone radionuclide scintigraphy. BCR was defined as 
the first increase in PSA levels (≥ 0.2 ng/mL), with levels 
not decreasing to undetectable limits, after radical pros-
tatectomy.
Statistical analyses
Student t-test and χ2 test were used to compare the sig-
nificance of the difference in means and proportions 
of the clinical characteristics and perioperative patient 
characteristics, respectively. The log-rank test was used 
to compare the BCR risk and BCR-free survival rate 
difference among the low-intermediate-risk, 1 high-risk 
factor, and ≥ 2 high-risk factors groups. Cox proportional 
hazards regression analysis was performed to define the 
prognostic factors. All statistical analyses were performed 
using Easy R (EZR; Saitama Medical Center, Jichi Med-
ical University, Saitama, Japan).7 Significance was con-
sidered at P < 0.05. The association between BCR-free 
survival and perioperative factors was evaluated.
RESULTS
Patient characteristics
The characteristics of low-intermediate-risk and high-
risk prostate cancer patients are shown in Table 1. No 
difference with regard to age, body mass index, and 
prostate volume between the low-intermediate-risk and 
high-risk prostate cancer patients was found. Of the 100 
high-risk prostate cancer patients, 24 had ≥ cT3, 87 had 
GS ≥ 8, and 14 had PSA ≥ 20 ng/mL.
 The pathological characteristics of the 241 patients 
who underwent RARP are shown in Table 2. A positive 
surgical margin (PSM) was identified in 44 patients 
(27 low-intermediate-risk and 17 high-risk patients). 
Extra-prostatic extension (EPE) was identified in 33 
patients, but was not evaluated in 30 patients because 
either the prostrate was cut or EPE in the prostate apex 
could not be detected. Seminal vesicle invasion and 
lymph node metastasis occurred in 7 and 6 high-risk 
prostate cancer patients, respectively. The median fol-
low-up period was 27 months, and BCR occurred in 19 
(7.9%) patients. The 1- and 3-year BCR-free survival 
rates for high-risk prostate cancer patients were 89.0% 
and 85.5%, respectively, while those for low-intermedi-
ate-risk prostate cancer patients were similar at 95.7%.
Clinicopathological characteristics of the high-risk 
prostate cancer patients
Table 3 shows that of the 100 high-risk prostate cancer pa-
tients, 77 had 1 high-risk factor (median age at surgery, 66 
years; median follow-up period, 24 months) and 23 had ≥ 2 
high-risk factors (median age at surgery, 63 years; median 
follow-up period, 12 months). The median PSA levels and 
the ratio of ≥ cT3 were significantly higher in the ≥ 2 high-
risk factors group than in the 1 high-risk factor group. BCR 
occurred in 6 (7.8%) patients who had 1 high-risk factor 
and in 7 (30.4%) patients who had ≥ 2 high-risk factors. The 
ratio of lymph node metastasis and seminal vesicle invasion 
was higher in patients who had ≥ 2 high-risk factors than in 
those who had 1 high-risk factor. The median time to pro-
gression of the two groups was 3 months. Of the 6 high-risk 
prostate cancer patients with lymph node metastasis, 5 had 
a BCR and received adjuvant or salvage hormone therapy.
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Table 1. Clinical characteristics of the low-intermediate and high risk prostate cancer patients
NCCN risk group
Low and intermediate risk 
(n = 141)
High risk
(n = 100) P-value
Median age (year, range) 65 (50–76) 66 (48–76) 0.738
Median body mass index (kg/m2, range) 23.4 (18.6–30.6) 24.0 (18.0–29.8) 0.708
Median prostate volume (mL, range) 29.6 (11.1–130.9) 27.0 (10.0–68.3) 0.012
Median preoperative PSA (ng/mL, range)
Total 7.69 (1.17–19.4) 8.64 (3.8–50.5) < 0.001
Preoperative PSA (n, %) < 0.001
≤ 20 141 (100.0) 86 (86.0)
> 20 – 14 (14.0)
Biopsy Gleason score (n, %) < 0.001
2–6 48 (34.0) 2 (2.0)
7 93 (66.0) 11 (11.0)
8–10 – 87 (87.0)
Clinical T stage (n, %) < 0.001
T1a–c 40 (28.4) 11 (11.0)
T2a–c 101 (71.6) 65 (65.0)
T3a – 24 (24.0）
NCCN, National Comprehensive Cancer Network; PSA, prostate-specific antigen. 
Table 2. Pathological characteristics of the low-intermediate and high risk prostate cancer patients
NCCN risk group
Low and Intermediate risk
(n = 141) 
High risk
(n = 100) P-value
Pathological T Stage (n, %) 0.01
pT2a–c 127 (90.1) 80 (80.0)
pT3a–b 14 (9.9) 20 (20.0)
Gleason score (n, %) < 0.01
6 23 (16.3) 3 (3.0)
7 104 (73.8) 62 (62.0)
8–10 14 (9.9) 35 (35.0)
Nerve sparing (n, %) 94/141 (66.7) 19 (19.0) < 0.01
Lymph node dissection (n, %) 101 (71.6) 100 (100.0)
Limited / Extended (n) 101/0 34/66
Median Nodes removed (range) 8.1 (2–23) 15.9 (3–40) < 0.01
EPE Total (n, %) 0.04
 Positive 15 (10.6) 18 (18.0)
 Negative 105 (74.5) 73 (73.0)
 Unknown 21 (14.9) 9 (9.0)
PSM Total (n, %) 27 (19.1) 17 (17.0) 0.62
Lymph node metastasis (n, %) 1 (0.7) 6 (6.0) 0.04
Seminal vesicle invasion (n, %) 0 (0) 7 (7.0) 0.02
Follow-up time, months, median (range) 30 (3–60) 24 (0–60)
BCR free survival rates 1-year (%) 95.7 89.0 0.01
 3-year (%) 95.7 85.5 0.01
BCR, biochemical recurrence; EPE, extra-prostatic extension; NCCN, National Comprehensive Cancer Network; PSM, positive surgical 
margin. 
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Table 3. Clinicopathological characteristics of the high risk prostate cancer patients
The Number of NCCN high risk factor 　
One factor 
(n = 77)
Two or more factors 
(n = 23) P-value
Median age (year, range) 66 (49–75) 63 (55–73) 0.187
Median prostate volume (mL, range) 28.6 (14.5–68.3) 26.0 (10–60) 0.58
Median Preoperative PSA (ng/mL, range) 8.14 (4.1–34.6) 14.98 (6.9–39.2) 0.001
Clinical T stage [≥ cT3 (n, %)] 7 (9.1) 17 (73.9) 0.001
Biopsy GS [≥ 8 (n, %)] 65 (84.4) 22 (95.7) 0.288
Extended lymph node dissection {n, %} 45 (58.4) 21 (91.3) 0.003
Pathological T stage [≥ pT3 ( n, %)] 13 (16.9) 7 (30.4) 0.232
Pathological GS [≥ 8 ( n, %)] 24 (31.2) 11 (47.8) 0.212
Median nodes removed (median, range) 11 (3–39) 20 (4–31) 0.837
EPE positive (n, %) 13 (16.9) 6 (26.1) 0.36
PSM (n, %) 10 (13.0) 7 (30.4) 0.063
Lymph node metastasis (n, %) 2 (2.6) 4 (17.4) 0.024
Seminal vesicle invasion (n, %) 1 (1.3) 5 (21.7) 0.002
Follow-up time, months, median (range) 24 (0–60) 12 (0–45) 0.001
EPE, extra-prostatic extension; GS, Gleason score; NCCN, National Comprehensive Cancer Network; PSA, prostate-specific antigen; 
PSM, positive surgical margin. 
Table 4. Univariate and multivariate logistic regression analyses for BCR prediction in high-risk prostate cancer 
patients 
　 　 Univariate Multivariate
Preoperative predictors P-value HR 95% CI P-value
Age (year) ≥ 65 vs < 65 0.104 0.230
BMI （kg/m2） ≥ 25 vs < 25 0.773
Prostate volume (mL) ≥ 40 vs < 40 0.320
PSA （ng/mL） ≥ 20 vs < 20 0.774 0.568
PSA density (ng/mL/mL) ≥ 0.3 vs < 0.3 0.423
Biopsy GS ≥ 8 vs < 8 0.156 0.998
Clinical T stage ≥ T3 vs ≤ T2c 0.036 4.052 1.26–12.99 0.019
Nerve sparing (+) vs (–) 0.664
Lymph node dissection Limited vs extended 0.959
postoperative predictors
Pathological T stage ≥ pT3 vs ≤ pT2c 0.077 0.573
Pathological Gleason score ≥ 8 vs < 8 0.339
EPE (+) vs (–) 0.001 0.634
PSM (+) vs (–) < 0.001 17.21 2.65–111.8 0.003
Lymph node metastasis (+) vs (–) < 0.001 18.3 1.35–248.7 0.029
Seminal vesicle invasion (+) vs (–) 0.003 0.242
BCR, biochemical recurrence; BMI, body mass index; CI, confidence interval; EPE, eextra-prostatic extension; GS, Gleason score; HR, 
hazard ratio; PSA, prostate-specific antigen; PSM, positive surgical margin.
Identification of perioperative predictors of BCR-
free survival in high-risk prostate cancer patients
Univariate and multivariate analyses showed that cT3 
was significantly associated with BCR [hazard ratio 
(HR) = 4.052; 95% confidence interval (CI), 1.26–12.99; 
P = 0.019]. However, no difference in BCR rates in the 
1 high-risk factor group was observed (≥ cT3 vs. GS ≥ 
8, P = 0.429; PSA ≥ 20 vs. GS ≥ 8, P = 0.523; ≥ cT3 vs. 
PSA ≥ 20, P = 1). Performing nerve-sparing surgery and 
extended lymph node dissection showed no effects on 
the BCR-free rates. Additionally, multivariate analysis 
showed that PSM (HR = 17.21; 95% CI, 2.65–111.8; P = 
0.003) and lymph node metastasis (HR = 18.3; 95% CI, 
1.35–248.7; P = 0.029), as postoperative factors, were 
significantly associated with BCR (Table 4).
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Fig. 1. BCR-free survival rate after RARP for low-intermediate-risk and high-risk prostate cancer patients, according to the number of 
NCCN risk factors. Low and intermediate risk versus 1 high-risk factor, log-rank P = 0.251; low and intermediate risk versus ≥ 2 high-
risk factors, log-rank P = 0.001; 1 high-risk factor versus ≥ 2 high-risk factors, log-rank P = 0.002. BCR, biochemical recurrence; NCCN, 
National Comprehensive Cancer Network; RARP, robot-assisted radical prostatectomy.
Table 5. Univariate and multivariate logistic regression analyses for preoperative BCR prediction in high-risk 
prostate cancer patients including a number of high-risk factors
Univariate Multivariate
Preoperative predictors P-value HR 95% CI P-value
Age (year) ≥ 65 vs < 65 0.104 0.320
BMI （kg/m2） ≥ 25 vs < 25 0.773
Prostate volume (mL) ≥ 40 vs < 40 0.320
PSA （ng/mL） ≥ 20 vs < 20 0.774
PSA density (ng/mL/mL) ≥ 0.3 vs < 0.3 0.423
Biopsy GS ≥ 8 vs < 8 0.156 0.998
Clinical T stage ≥ T3 vs ≤ T2c 0.036 0.792
NCCN high-risk factors ≥ 2 vs 1 0.002 4.624 1.54–13.89 0.006
Nerve sparing (+) vs (–) 0.664
Lymph node dissection Limited vs extended 0.959
BCR, biochemical recurrence; BMI, body mass index; CI, confidence interval; GS, Gleason score; HR, hazard ratio; NCCN, National 
Comprehensive Cancer Network; PSA, prostate-specific antigen.
BCR-free survival according to the number of 
NCCN risk factors
The 1-year BCR-free survival rate of patients with 1 
high-risk factor and those with > 2 high-risk factors was 
94.8% and 69.6%, respectively. Patients with ≥ 2 high-
risk factors were significantly associated with BCR (P 
= 0.002). However, no difference in BCR rates between 
patients with 1 high-risk factor and low-intermedi-
ate-risk patients was found (P = 0.251) (Fig. 1). In the 
multivariate analysis for preoperative BCR prediction, 
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≥ 2 high-risk factors were significantly associated with 
BCR (P = 0.006) (Table 5).
DISCUSSION
Radical prostatectomy, hormone therapy, and RT are the 
treatments available for prostate cancer. However, ob-
taining a sufficient therapeutic effect using one therapy 
only for high-risk prostate cancer is difficult.8, 9 Long-
term hormone therapy plus RT was considered the stan-
dard treatment for localized high-risk prostate cancer.10 
Hanks GE et al. reported that long-term ADT (2 years) 
plus RT for patients with a GS 8–10 locally advanced 
prostate cancer is associated with a 5-year biochemical 
failure rate of 33.4%, which means that one-third of 
patients with high-risk prostate cancer under long-term 
ADT plus RT have a BCR within 5 years.1 Wirth et al. 
reported that adjuvant hormone therapy following radi-
cal prostatectomy improves progression-free survival in 
some patients with advanced prostate cancer.11 Bolla et 
al. reported that adjuvant RT after radical prostatecto-
my in patients with high-risk prostate cancer improves 
10-year BCR-free survival rates.12 Moreover, with the 
recent spread of awareness regarding PSA screening 
and RARP, a trend has been demonstrated toward an 
improved pathologic stage in carefully selected patients 
with a high clinical stage. Such difference may suggest 
an expanded role of RARP in prostate cancer.13, 14 Nev-
ertheless, not all high-risk prostate cancer patients bene-
fit from radical prostatectomy only. Thus, we investigat-
ed the predictive factors for BCR and BCR-free survival 
rates with the number of NCCN high-risk factors for 
high-risk prostate cancer patients who underwent RARP.
 In this study, the preoperative and postoperative 
factors of BCR are ≥ cT3, PSM, and lymph node metas-
tasis (Table 4). In previous reports, PSM, seminal vesicle 
invasion, pathologic GS (GS ≥ 8), pathologic T stage 
(≥ pT3a), and lymph node metastasis were identified as 
the postoperative factors predicting BCR.15, 16 On the 
other hand, Steuber et al. assessed the prognostic role of 
radical prostatectomy in lymph-node-positive prostate 
cancer patients and reported that radical prostatectomy 
improves progression-free and cancer-specific survival.17 
Jaunarena et al. reported that radical prostatectomy has 
been superior in getting better local control of prostate 
cancer, making radiation therapy and hormone therapy 
as secondary therapies.18 In our study, we consider that 
RARP, as a local therapy, contributed to good prognosis 
in high-risk prostate cancer patients.
 In relation to nerve sparing, Lavery et al. reported 
that of 123 patients who underwent RARP at their in-
stitution, 42% underwent nerve-sparing surgery, with 
safe and effective outcomes.19 Recabal et al. analyzed 
the efficacy of radical prostatectomy in achieving com-
plete primary tumor excision while preserving erectile 
function in high-risk prostate cancer patients. Of 584 
patients, 515 (88%) had some degree of bilateral neuro-
vascular bundle preservation, of which 125 (24%) had 
a PSM. Of 160 patients with preoperatively functional 
erections and available erectile function follow-up, 75 
(47%) had recovered erectile function within 2 years. 
Moreover, they reported that high-risk prostate cancer 
should not be considered an indication for complete 
bilateral neurovascular bundle resection.20 In our study, 
performing nerve-sparing surgery or not showed no ef-
fects on the BCR-free rates (graph not shown P = 0.664).
 Although cT3 was significantly associated with 
BCR, no difference in BCR rates in the 1 high-risk fac-
tor group was observed. However, a significant differ-
ence in BCR-free survival rates between patients with 
1 high-risk factor and those with ≥ 2 high-risk factors 
was found (P = 0.002). The 1-year BCR-free survival 
rate of patients with 1 high-risk factor and those with ≥ 
2 high-risk factors was 94.8% and 69.6%, respectively. 
No significant difference in BCR-free survival rates be-
tween patients with 1 high-risk factor and low-interme-
diate-risk patients was observed.
 Several studies have attempted to elucidate whether 
a difference in postoperative outcomes according to the 
number and combination of high-risk factors exists.4, 
21, 22 Jung Ki et al. analyzed 546 patients, classified as 
high-risk according to the NCCN risk classification and 
who underwent radical prostatectomy between 2006 and 
2013, and reported significant differences in BCR-free 
survival rates between patients with 1 high-risk factor 
and those with ≥ 2 high-risk factors. They divided the 
546 high-risk prostate cancer patients into two groups: 
unfavorable group (biopsy GS primary pattern 5 and/
or the presence of ≥ 2 high-risk factors) and favorable 
group (all others). Significant differences in 5-year BCR-
free survival rates between the favorable (56.35%) and 
unfavorable (18.75%) groups were noted.21 In addition, 
Huai et al. analyzed 85 patients, classified as high-risk 
based on the D A`mico risk classification and who un-
derwent laparoscopic radical prostatectomy between 
2002 and 2009, and reported significant differences in 
BCR-free survival rates between patients with 1 high-
risk factor and those with ≥ 2 high-risk factors.4 Joniau 
et al. analyzed 1,360 high-risk prostate cancer patients 
who underwent radical prostatectomy between 1987 and 
2009 at 8 European high-volume centers and divided the 
patients into three groups: good prognosis (1 high-risk 
factor), intermediate prognosis (PSA levels > 20 ng/mL 
and stage cT3–4), and poor prognosis (GS 8–10 in com-
bination with at least 1 other high-risk factor). They re-
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ported a significant difference in cancer-specific survival 
rates among the groups. The good prognosis subgroup 
had exceptionally good 10-year prostate cancer-specific 
survival (95.4%). The poor prognosis subgroup needed 
much more multimodal treatment, and their 10-year 
prostate cancer-specific survival was significantly worse 
(79.7%).22 These findings and our study results show that 
prostate cancer patients with only 1 high-risk factor may 
be considered for RARP only.
 This study has certain limitations. First, our study 
was retrospective. Second, not all patients underwent ex-
tended lymph node dissection. Pierro et al. and the EAU 
guidelines have recommended high-risk prostate cancer 
patients to undergo extended lymph node dissection.23 
This may have influenced the BCR rates in our study. 
Third, the number of patients was small and the obser-
vation period was short. Of 77 patients who had 1 high-
risk factor, 7, 5, and 65 patients had ≥ cT3, PSA ≥ 20, 
and GS ≥ 8, respectively. Although cT3 was significantly 
associated with BCR in patients with 1 high-risk factor, 
6 patients with BCR had GS ≥ 8. The verification of the 
combination of cT3 and other factors were not sufficient 
because of the small number of concerned patients. 
Thus, further continued observation with a larger num-
ber of patients is warranted.
 In conclusion, high-risk prostate cancer patients 
with only 1 NCCN high-risk factor can be considered 
for RARP only. The patients with ≥ 2 high-risk factors 
should be considered for a multimodal treatment strategy.
The authors declare no conflict of interest.
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